Pregabalin Capsule
Product Images NDC 71335-1505

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1505). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351505)

Label for Pregabalin Capsules, USP 300 mg by Bryant Ranch Prepack (BRP Pharmaceuticals). The label shows a 60-capsule package size with the NDC 71335-1505-01. It includes storage instructions and a barcode, along with the notation Rx only.*

FDA Label Image

Label (Lbl7133515052)

The label for Pregabalin 300 mg capsules by Bryant Ranch Prepack, NDC 71335-1505. It states the product is a red capsule, compared to Lyrica 300 mg capsules from Laurus Labs Limited, with package quantity of 60 capsules. The label includes storage instructions (20°-25°C) and a warning to keep drugs out of children's reach.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure diagram depicting the molecular formula of Pregabalin, the active ingredient in the product PREGABALIN 300 mg by Bryant Ranch Prepack.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula representing creatinine clearance (CLCr) calculation, incorporating age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph displaying the percent of patients improved on the vertical axis against percent improvement in pain from baseline on the horizontal axis. Four lines represent different groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing comparative patient improvement across varying dosage levels.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A line chart comparing the percent of patients improved against the percent improvement in pain from baseline. The chart shows two lines representing Pregabalin 100 mg three times a day and placebo, with the Pregabalin line consistently above the placebo line, indicating greater patient improvement at various pain reduction thresholds.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin 300 mg, 150 mg, 75 mg twice a day, and placebo, showing different levels of patient improvement across these treatment groups.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph showing percent improvement in pain from baseline (x-axis) versus percent of patients improved (y-axis). It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph illustrates the higher percentage of patients improved with the 200 mg dose compared to 100 mg and placebo.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The Y-axis represents patient improvement percentage, and the X-axis shows percent pain improvement.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

A bar graph depicting responder rates (%) for different dosages of pregabalin compared to placebo in two clinical studies, Study E1 and Study E3. The graph shows increasing responder rates with higher pregabalin doses, with statistical significance indicated against placebo for several dose groups.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph depicting seizure reduction as median percent change from baseline versus dose in mg/day. The graph includes four studies (E1 BD, E2 TID, E3 BD, E3 TID) shown with different markers. Significant p-values are displayed near data points, indicating statistical significance. Dose ranges from 0 to 600 mg/day with effects on seizure reduction measured up to 60%.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line graph displaying percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares four groups: Pregabalin 600 mg daily dose, 450 mg daily dose, 300 mg daily dose, and placebo, illustrating patient improvement trends at different dose levels.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without loss to treatment response (LTR) over 180 days for Pregabalin versus placebo. The x-axis shows days from 0 to 180, and the y-axis shows the estimated percentage of subjects without LTR from 0% to 100%. The solid line represents Pregabalin and the dashed line represents placebo.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph comparing the percentage of subjects improved from baseline to week 12 between Pregabalin and placebo groups. The x-axis shows percent improvement from baseline up to 100%, and the y-axis shows the percent of subjects improved. The solid line represents Pregabalin, showing higher improvement percentages compared to the dotted line representing placebo.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line graph comparing the percentage of subjects improved from baseline to week 16 BOCF for Pregabalin versus Placebo. The x-axis represents percent improvement from 0 to 100, and the y-axis represents the percent of subjects improved. The Pregabalin treatment shows a higher percentage of subjects improved compared to Placebo across most improvement levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.